The Fly | OCGN

Ocugen

· OCGN

Dashboard

Financials

Ratios

Transcripts

Valuation

Over a week ago

Largest borrow rate increases among liquid names

May 29, 8:45 AM

Ocugen price target lowered by $1 at Canaccord, here's why

OCGN

May 27, 6:58 AM

Ocugen reports Q1 EPS (6c), consensus (5c)

OCGN

May 5, 8:40 AM

Ocugen announces private offering of $115M of convertible senior notes

OCGN

May 4, 4:05 PM

Ocugen completes dosing in GARDian3 trial

OCGN

Apr 1, 7:25 AM

Chardan sees positive read-through to Annexon's vonaprument from Apellis deal

Mar 31, 1:07 PM

Ocugen price target raised by $4 at Noble Capital, here's why

OCGN

Mar 25, 9:18 AM

Ocugen price target raised by $3 at H.C. Wainwright, here's why

OCGN

Mar 25, 6:05 AM

What You Missed On Wall Street On Tuesday

+20

Mar 24, 4:16 PM

Midday Fly By: Estee Lauder in deal talks with Puig, Smithfield reports Q4 beat

+26

Mar 24, 11:58 AM

Ocugen announces 12-month data from ArMaDa clinical trial of OCU410

OCGN

Mar 24, 7:54 AM

What You Missed On Wall Street On Tuesday

+23

Mar 17, 4:31 PM

Midday Fly By: Nvidia bullish on AI revenue, MasterCard to acquire BVNK

+23

Mar 17, 11:49 AM

Ocugen initiated with bullish view at Canaccord, here's why

OCGN

Mar 17, 7:29 AM

What You Missed On Wall Street On Wednesday

+24

Mar 11, 4:21 PM

Midday Fly By: IEA to release 400M oil barrels, Oracle reports Q3 beat

+24

Mar 11, 11:57 AM

Ocugen initiated with bullish view at Oppenheimer, here's why

OCGN

Mar 11, 6:36 AM

Ocugen price target raised by $7 at Lucid Capital, here's why

OCGN

Mar 11, 6:07 AM

Ocugen reports Q4 EPS (6c), consensus (6c)

OCGN

Mar 4, 8:21 AM

Ocugen announces enrollment for Phase 3 liMeliGhT trial is complete

OCGN

Mar 2, 7:24 AM

Ocugen appoints Rita Johnson-Greene as CFO

OCGN

Feb 9, 7:19 AM

What You Missed On Wall Street On Wednesday

+26

Jan 21, 4:11 PM

Midday Fly By: Netflix reports Q4 beat, Smithfield to acquire Nathan's

+26

Jan 21, 12:02 PM

Ocugen prices 15M shares at $1.50 in underwritten offering

OCGN

Jan 21, 8:34 AM

What You Missed On Wall Street On Thursday

+45

Jan 15, 4:18 PM

Modifier Gene Therapy Platform: A novel approach for treating inherited retinal diseases by targeting common pathways rather than specific gene mutations, potentially enabling a single therapeutic to address a broad patient population.

High Unmet Medical Need Focus: Prioritizing devastating inherited retinal diseases and other ocular conditions with limited or no current treatment options, addressing significant market opportunities and patient suffering.

Advanced Gene Therapy Pipeline: A robust and diversified pipeline of gene therapies (OCU400, OCU410, OCU200) addressing multiple ocular indications, providing varied opportunities for success.

Clinical Trial Uncertainty: The success of OCGN's investigational gene therapies in clinical trials is not guaranteed, and unfavorable results could significantly impact their pipeline.

Regulatory Approval Challenges: OCGN may fail to obtain necessary regulatory approvals from bodies like the FDA for its product candidates, delaying or preventing market entry.

Funding and Dilution Needs: OCGN is a development-stage company requiring substantial capital to fund its operations, which may lead to future equity offerings and shareholder dilution.

Charts

Advanced Gene Therapy Pipeline: A robust and diversified pipeline of gene therapies (OCU400, OCU410, OCU200) addressing multiple ocular indications, providing varied opportunities for success.

Clinical Trial Uncertainty: The success of OCGN's investigational gene therapies in clinical trials is not guaranteed, and unfavorable results could significantly impact their pipeline.

Regulatory Approval Challenges: OCGN may fail to obtain necessary regulatory approvals from bodies like the FDA for its product candidates, delaying or preventing market entry.

Funding and Dilution Needs: OCGN is a development-stage company requiring substantial capital to fund its operations, which may lead to future equity offerings and shareholder dilution.